Business Wire

NIPPON-SHOKUBAI

Share
Nippon Shokubai’s Newly Developed Material Contributed the Successful Demonstration of Groundbreaking Renewable Seawater Desalination Plant in Hawaii

NIPPON SHOKUBAI CO., LTD. (Headquarters: Osaka, Japan, President: Kazuhiro Noda, hereinafter "Nippon Shokubai")(TOKYO:4114) combined forces with Trevi Systems Inc. (Headquarters: California, USA, CEO: John Webley, hereinafter “Trevi Systems” *1) in the development of the draw solution as a key component in the forward osmosis (hereinafter “FO”) system, which is a next generation system for seawater desalination and water treatment. With $4 million grant from US Department of Energy, Trevi Systems commenced a large scale project to demonstrate the production of fresh water at a volume of 500 m3 per day from seawater using the jointly developed draw solution on the islands of Hawaii in June, 2022 (*2) and completed the data collection in September, 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240216286680/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Figure 1 Comparison between RO system and FO system (Graphic: Business Wire)

In recent years, water shortage has become a serious problem in the world, and reverse osmosis (hereinafter “RO”) is widely used in the seawater desalination for agricultural and drinking water use and for treatment of industrial water. The RO system is a technology that involves the pressurization of seawater or wastewater over an RO membrane to remove salts (such as NaCl) and impurities. While this system enables the acquisition of high quality water, the large amount of electric power consumed by the pressurizing pump is considered an issue (Figure 1).

Meanwhile, the FO system is focused on as a means that will resolve this issue. The FO system utilizes the osmosis, which is a natural process and occurs when liquids of differing solute concentrations are separated by a semi-permeable membrane and water moves by the process of osmosis from the solution of lower concentration to that of higher concentration. In the seawater desalination, the FO system utilizes the difference in solute concentration in seawater and draw solution, and the natural osmotic pressure as a result of the draw solution on one side of a FO membrane (a semi-permeable membrane) to pull / transport fresh water from seawater into the draw solution with everything taking place under low pressure and energy conditions (Figure 1). Nippon Shokubai and Trevi Systems developed the draw solution to be separated from the recovered water using low grade thermal heat (Photo 1).

Trevi Systems is a company in the United States which was founded in 2010. Key elements of Trevi Systems’ FO system are the use of retrograde thermolytic solute draw solution and recycling of the draw solute back to the FO membrane (Figure 2). Trevi Systems conducted a pilot test to demonstrate the production of fresh water at a volume of 50 m3 per day from seawater in Middle East (the UAE) in 2016, which confirmed that the use of the FO system was able to reduce electric power consumption to about 1/3 compared to that of the RO system.

However, the improvement in the amount of water production is necessary for the widespread utilization of the FO system at full scale, and the improvement in the function of the draw solution as the key component is crucial for realizing this. Nippon Shokubai and Trevi Systems have successfully developed a draw solution with the capability of improving water production by 30% compared with the previous product. This developed draw solution was used in the demonstration pilot plant (500m3/day) operated by Trevi Systems on the islands of Hawaii (*2).

Key achievements of the project include:

  1. The fresh water recovery ratio from seawater exceeded 65% surpassing commercial RO systems’ capabilities.
  2. Electrical energy consumption is 1/3 compared with RO systems.
  3. Competitive Capital Costs: Demonstrated capital costs competitive with existing RO desalination systems.

Trevi Systems is committed to further expanding the NELHA plant’s capabilities, with plans to increase capacity to over 6,000m3/day at the same site, and showcasing the potential for zero liquid discharge (*3) by the use of brine and brine concentration for mineral recovery.

The FO system is under consideration to be introduced for seawater desalination in areas with high demand for water, such as the Middle East, as well as for brine concentration to achieve zero liquid discharge. Nippon Shokubai will make further efforts to improve the performance and functions of the draw solution with a view toward future expansion of the FO system.

*1: About Trevi Systems
Trevi Systems Inc. is California based company who is a pioneer in forward osmosis technology for sustainable and efficient water desalination and brine concentration. With a commitment to innovation and environmental responsibility, Trevi Systems continues to redefine the possibilities in utilizing forward osmosis and pressurized forward osmosis to deliver clean water and other resources from the most challenging wastewaters.
For more information: https://www.trevisystems.com/

*2: FO seawater desalination project in Hawaii
The FO system by Trevi Systems was adopted in the Sun Shot program by the Department of Energy, USA. An experiment will be conducted to demonstrate the desalination of seawater using the solar heat collection facility owned by the Natural Energy Laboratory of the Hawaii Authority (NELHA).

*3: zero liquid discharge (ZLD)
One of water treatment processes intended to reduce wastewater and produce clean water that is suitable for reuse. ZLD systems purify and recycle virtually all wastewater received.

The press release issued by Nippon Shokubai is here.

The press release issued by Trevi Systems is here.

About NIPPON SHOKUBAI CO., LTD.: Nippon Shokubai utilizes the unique technology to manufacture chemicals such as ethylene oxide, acrylic acids, catalysts, superabsorbent polymers. We use chemistry to make the impossible possible, and offer unprecedented solutions to the world, specifically in Environment & Energy, Electronics & Imaging and Daily Use fields. Our corporate mission is "TechnoAmenity: Providing prosperity and comfort to people and society with our unique technology".
For more information: https://www.shokubai.co.jp/en

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240216286680/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye